FDA Guidance Opens Door for Wearables to Track Blood Pressure Without Medical Device Clearance

The FDA has officially opened a regulatory fast-lane for the next generation of consumer wearables. Following a sweeping update to its "General Wellness" policy in January 2026, the agency has clarified that noninvasive devices tracking blood pressure, oxygen saturation, and even blood glucose can bypass strict medical device clearance—provided they are marketed strictly for lifestyle and wellness purposes.[2][3]

The policy shift marks a profound departure from the FDA's historical stance, which previously held that measuring clinical vital signs was inherently a medical function. By focusing on a product's "intended use" rather than its technical capabilities, the agency is allowing tech companies to deploy advanced biometric sensors without spending years navigating the costly 510(k) clearance process.[4][6]

The real-world impact of this guidance crystallized in June 2026, when the FDA formally closed a nearly year-long enforcement action against fitness wearable maker WHOOP. The agency had previously targeted the company's "Blood Pressure Insights" feature, but dropped the warning letter after WHOOP made visual and labeling adjustments to ensure the tool did not mimic a clinical diagnostic device.[1]

For the booming wearable industry, the resolution is a watershed moment. Companies like Apple, Oura, and Garmin now have a clear legal framework to introduce cuffless blood pressure monitoring and other advanced metrics, provided they carefully thread the needle of regulatory language.[2]

To understand the magnitude of this shift, one must look back to July 2025. At the time, the FDA issued a high-profile warning letter to WHOOP, arguing that estimating blood pressure was "inherently associated with the diagnosis of hypo- and hypertension." The agency's position was that no amount of disclaimer text could transform a blood pressure monitor into a mere wellness tracker.[4][6]

That "inherent association" doctrine sent a chill through the digital health sector. If any biometric capable of diagnosing a disease automatically triggered medical device regulation, the development of consumer health trackers would face a massive regulatory bottleneck.[6]

However, under the leadership of FDA Commissioner Dr. Marty Makary, the agency reversed course in early 2026. Makary emphasized the need to promote innovation, particularly in artificial intelligence and sensor technology, arguing that consumers benefit from early awareness of their physiological baselines.[3]

The revised January 2026 guidance establishes two primary criteria for the general wellness exemption. First, the product must present a low risk to users, meaning it relies on noninvasive technologies like optical sensors rather than needles or implants. Second, its intended use must be strictly limited to maintaining a healthy lifestyle, with no claims of diagnosing, curing, or mitigating disease.[4]

Crucially, the guidance explicitly lists blood pressure and oxygen saturation as parameters that can fall under this umbrella. A smartwatch can now legally display a user's blood pressure trends alongside their sleep data and pulse rate, so long as the interface does not prompt the user to adjust their medication or substitute the reading for a doctor's visit.[3][4]

Legal analysts note that the boundary between a wellness product and a medical device now hinges entirely on marketing and presentation. If a company claims its wearable provides "medical-grade" accuracy or uses color-coding that mimics clinical hypertension charts, it crosses the line into regulated territory.[4]

This regulatory nuance explains how WHOOP resolved its FDA dispute. By making targeted modifications to the labeling and visual presentation of its Blood Pressure Insights feature, the company reinforced its wellness purpose without altering the underlying algorithm.[1]

The technology driving this trend relies heavily on photoplethysmography (PPG)—the green or red optical sensors found on the underside of most smartwatches. Rather than physically compressing an artery like a traditional blood pressure cuff, these sensors measure the volumetric changes in blood flow with each heartbeat.

Machine learning algorithms then analyze these optical signals, alongside metrics like heart rate variability, to infer blood pressure trends. Because these estimates are derived rather than directly measured, they are particularly well-suited for the FDA's new wellness framework, which permits the display of "trends, baselines, or longitudinal summaries."

Despite the enthusiasm from the tech sector, the FDA's relaxed oversight has sparked deep concern among clinical researchers and medical professionals. The primary fear is that consumers will inevitably use wellness data to make medical decisions, regardless of the legal disclaimers buried in a user agreement.[5]

Researchers at institutions like Duke University point out that while abnormal readings from a wearable often prompt users to seek clinical confirmation, falsely "normal" readings present a hidden danger. If a consumer with undiagnosed hypertension sees a normal blood pressure trend on their smartwatch, they may be falsely reassured and delay seeking necessary medical care.[5]

Furthermore, the accuracy of optical blood pressure estimation remains highly variable. Skin pigmentation, wrist placement, and ambient temperature can all significantly degrade the quality of PPG signals, leading to erroneous data that the FDA will no longer actively police under the wellness exemption.[5]

The guidance does require that if a wellness product displays values that mimic clinical measurements—such as millimeters of mercury (mmHg) for blood pressure—those values must be validated through manufacturer testing or peer-reviewed literature. However, this validation does not undergo the rigorous premarket review required for a 510(k) clearance.

Ultimately, the FDA's 2026 guidance represents a calculated gamble. The agency is betting that the public health benefits of widespread, continuous biometric tracking outweigh the risks of consumer misinterpretation. As wearables evolve from simple step counters into sophisticated physiological dashboards, the responsibility for interpreting that data is shifting squarely onto the shoulders of the user.[2][5]